ArticleInfection2026
Pathogen identification and outcome in adult patients with community-acquired pneumonia in Switzerland: findings from the Swiss CAPNETZ cohort study.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Pneumococcal serotype distribution and diagnostic yield of serotype-specific urinary antigen detection in adults with CAP in Switzerland, 2016-2021: a prospective cohort study.BMC infectious diseases · 2026Article
- Forecasting the Multidimensional Burdens of Hospital Admissions in LRTIs and COPD: Projections of Healthcare Expenditures, Resource Utilization, and Socioeconomic and Environmental Outcomes for Switzerland.Infectious diseases and therapy · 2026Article
- Circulating alpha-1 antitrypsin and its c-terminal peptides differentiate bacterial from viral community-acquired pneumonia.Journal of translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCommunity-acquired pneumonia (CAP) causes significant morbidity and mortality, but Swiss data are limited. We analyzed the Swiss CAPNETZ cohort to describe patient characteristics, pathogens, diagnostics, and outcomes.
methodsAdults with CAP were prospectively enrolled between 2010 and 2022 at two tertiary hospitals. Data on demographics, comorbidities, microbiology, and outcomes were collected. Mortality was assessed at 28 and 180 days.
resultsAmong 478 patients, 97.7% were hospitalized (median 7 days), and 76.4% had ≥ 1 comorbidity. ICU admission occurred in 7.3%. Overall mortality was 2.9% at 28 days and 5.5% at 180 days, increasing during the COVID-19 pandemic (28-day: 5.7%; 180-day: 10.9%). Higher mortality was observed in older, immunosuppressed, and oncologic patients. The etiological pathogens were detected in 38.3%, and molecular testing of sputum and bronchioalveolar lavage (BAL) enhances pathogen detection rates. Bacterial monoinfections predominated (20.2%), followed by viral (7.4%) and mixed infections (9.5%). Leading pathogens were Streptococcus pneumoniae (35.0%) and Haemophilus influenzae (16.1%). In immunocompromised patients, H. influenzae predominated.
conclusionOverall mortality of CAP stays high. S. pneumoniae remains the most common pathogen overall, while H. influenzae is the most frequent pathogen in immunocompromised patients. Molecular testing of sputum and BAL improves pathogen detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.